FDA Approves Moderna's mRNA Flu Vaccine for Adults 50 and Older

The U.S. Food and Drug Administration (FDA) has approved Moderna's mFlusiva, the first mRNA flu vaccine, for individuals aged 50 and older. This marks a significant advancement in influenza prevention, utilizing the same mRNA technology as Moderna's COVID-19 vaccines. The vaccine received full approval for those aged 50 to 64 and accelerated approval for adults 65 and older, with further study required to confirm benefits for the older group.